{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:40:39Z","timestamp":1792525239800,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12149-026-02252-7","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:05:03Z","timestamp":1784664303000},"page":"1359-1369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protein expression of glucose metabolism and somatostatin receptor between primary tumor and distant metastasis in differentiated thyroid cancer"],"prefix":"10.1007","volume":"40","author":[{"given":"Joon Ho","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Kyung","family":"Myung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Seog","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Hyun","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-1659","authenticated-orcid":false,"given":"Ilhan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"3","key":"2252_CR1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/01.sla.0000250445.92336.2a","volume":"245","author":"BH Lang","year":"2007","unstructured":"Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245(3):366\u201378.","journal-title":"Ann Surg"},{"issue":"11","key":"2252_CR2","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1210\/jcem.84.11.6115","volume":"84","author":"Y Kitamura","year":"1999","unstructured":"Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab. 1999;84(11):4043\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2252_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.4158\/EP171924.OR","volume":"23","author":"D Hirsch","year":"2017","unstructured":"Hirsch D, Levy S, Tsvetov G, Gorshtein A, Slutzky-Shraga I, Akirov A, et al. Long-Term Outcomes and Prognostic Factors in Patients with Differentiated Thyroid Cancer and Distant Metastases. Endocr Pract. 2017;23(10):1193\u2013200.","journal-title":"Endocr Pract"},{"issue":"2","key":"2252_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3803\/EnM.2018.33.2.287","volume":"33","author":"H Kim","year":"2018","unstructured":"Kim H, Kim HI, Kim SW, Jung J, Jeon MJ, Kim WG, et al. Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea. Endocrinol Metab (Seoul). 2018;33(2):287\u201395.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"2252_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13139-024-00886-x","volume":"59","author":"SW Oh","year":"2025","unstructured":"Oh SW, Park S, Chong A, Kim K, Bang JI, Seo Y, et al. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-II. Nucl Med Mol Imaging. 2025;59(1):8\u201326.","journal-title":"Nucl Med Mol Imaging"},{"issue":"supplement 3","key":"2252_CR6","first-page":"1224","volume":"56","author":"JH Choi","year":"2015","unstructured":"Choi JH, Moon H, Park J, Chang K, Byun BH, Lim I, et al. Long-term outcomes of differentiated thyroid cancer with bone metastasis and the prognostic factors. J Nucl Med. 2015;56(supplement 3):1224\u20131224.","journal-title":"J Nucl Med"},{"issue":"2","key":"2252_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1089\/thy.2012.0654","volume":"24","author":"SW Cho","year":"2014","unstructured":"Cho SW, Choi HS, Yeom GJ, Lim JA, Moon JH, Park DJ, et al. Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors. Thyroid. 2014;24(2):277\u201386.","journal-title":"Thyroid"},{"issue":"2","key":"2252_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13139-017-0502-9","volume":"52","author":"JH Choi","year":"2018","unstructured":"Choi JH, Byun BH, Lim I, Moon H, Park J, Chang KJ, et al. The Predictive Values of Lesion Size, F-18 FDG Avidity and I-131 Avidity for the Clinical Outcome of I-131 Treatment in Patients with Metastatic Differentiated Thyroid Carcinoma Only in the Lung. Nucl Med Mol Imaging. 2018;52(2):135\u201343.","journal-title":"Nucl Med Mol Imaging"},{"issue":"8","key":"2252_CR9","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2252_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/cncr.22956","volume":"110","author":"E Sampson","year":"2007","unstructured":"Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007;110(7):1451\u20136.","journal-title":"Cancer"},{"issue":"23","key":"2252_CR11","doi-asserted-by":"publisher","first-page":"7209","DOI":"10.1158\/1078-0432.CCR-17-0306","volume":"23","author":"JG Joung","year":"2017","unstructured":"Joung JG, Oh BY, Hong HK, Al-Khalidi H, Al-Alem F, Lee HO, et al. Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer. Clin Cancer Res. 2017;23(23):7209\u201316.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2252_CR12","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/annonc\/mdx278","volume":"28","author":"Q Wei","year":"2017","unstructured":"Wei Q, Ye Z, Zhong X, Li L, Wang C, Myers RE, et al. Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis. Ann Oncol. 2017;28(9):2135\u201341.","journal-title":"Ann Oncol"},{"issue":"12","key":"2252_CR13","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1158\/0008-5472.CAN-17-2310","volume":"78","author":"W Schrijver","year":"2018","unstructured":"Schrijver W, Selenica P, Lee JY, Ng CKY, Burke KA, Piscuoglio S, et al. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. Cancer Res. 2018;78(12):3112\u201321.","journal-title":"Cancer Res"},{"issue":"15","key":"2252_CR14","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1158\/1078-0432.CCR-16-3115","volume":"23","author":"CKY Ng","year":"2017","unstructured":"Ng CKY, Bidard FC, Piscuoglio S, Geyer FC, Lim RS, de Bruijn I, et al. Genetic Heterogeneity in Therapy-Naive Synchronous Primary Breast Cancers and Their Metastases. Clin Cancer Res. 2017;23(15):4402\u201315.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2252_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/MPA.0000000000000570","volume":"45","author":"H Kimura","year":"2016","unstructured":"Kimura H, Ohtsuka T, Fujimoto T, Date K, Matsunaga T, Cases AI, et al. Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites. Pancreas. 2016;45(7):947\u201352.","journal-title":"Pancreas"},{"issue":"2","key":"2252_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1530\/ERC-14-0351","volume":"22","author":"S Le Pennec","year":"2015","unstructured":"Le Pennec S, Konopka T, Gacquer D, Fimereli D, Tarabichi M, Tomas G, et al. Intratumor heterogeneity and clonal evolution in an aggressive papillary thyroid cancer and matched metastases. Endocr Relat Cancer. 2015;22(2):205\u201316.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2252_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s12022-019-09593-2","volume":"30","author":"M Gawin","year":"2019","unstructured":"Gawin M, Kurczyk A, Stobiecka E, Fratczak K, Polanska J, Pietrowska M, et al. Molecular Heterogeneity of Papillary Thyroid Cancer: Comparison of Primary Tumors and Synchronous Metastases in Regional Lymph Nodes by Mass Spectrometry Imaging. Endocr Pathol. 2019;30(4):250\u201361.","journal-title":"Endocr Pathol"},{"key":"2252_CR18","doi-asserted-by":"publisher","first-page":"623182","DOI":"10.3389\/fendo.2021.623182","volume":"12","author":"CJ Gomes-Lima","year":"2021","unstructured":"Gomes-Lima CJ, Shobab L, Wu D, Ylli D, Bikas A, McCoy M, et al. Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ? Front Endocrinol (Lausanne). 2021;12:623182.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2252_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/lary.20073","volume":"119","author":"YH Jung","year":"2009","unstructured":"Jung YH, Hah JH, Sung MW, Kim KH, Cho SY, Jeon YK. Reciprocal immunohistochemical expression of sodium\/iodide symporter and hexokinase I in primary thyroid tumors with synchronous cervical metastasis. Laryngoscope. 2009;119(3):541\u20138.","journal-title":"Laryngoscope"},{"issue":"11","key":"2252_CR20","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1210\/jc.2003-032004","volume":"89","author":"A Rouxel","year":"2004","unstructured":"Rouxel A, Hejblum G, Bernier MO, Boelle PY, Menegaux F, Mansour G, et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2004;89(11):5362\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2252_CR21","first-page":"1857","volume":"82","author":"KB Ain","year":"1997","unstructured":"Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab. 1997;82(6):1857\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2252_CR22","first-page":"636","volume":"41","author":"EB Forssell-Aronsson","year":"2000","unstructured":"Forssell-Aronsson EB, Nilsson O, Bejegard SA, Kolby L, Bernhardt P, Molne J, et al. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 2000;41(4):636\u201342.","journal-title":"J Nucl Med"},{"issue":"5","key":"2252_CR23","first-page":"2161","volume":"86","author":"MC Zatelli","year":"2001","unstructured":"Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab. 2001;86(5):2161\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2252_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.tem.2005.11.005","volume":"17","author":"JJ Teunissen","year":"2006","unstructured":"Teunissen JJ, Kwekkeboom DJ, Krenning EP. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab. 2006;17(1):19\u201325.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2252_CR25","first-page":"39","volume":"4","author":"H Budiawan","year":"2013","unstructured":"Budiawan H, Salavati A, Kulkarni HR, Baum RP. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging. 2013;4(1):39\u201352.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"10","key":"2252_CR26","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1002\/cncr.24272","volume":"115","author":"F Iten","year":"2009","unstructured":"Iten F, Muller B, Schindler C, Rasch H, Rochlitz C, Oertli D, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer. 2009;115(10):2052\u201362.","journal-title":"Cancer"},{"issue":"3","key":"2252_CR27","first-page":"e49","volume":"53","author":"TT Htwe","year":"2012","unstructured":"Htwe TT, Karim N, Lam AK. Follicular thyroid carcinoma with insular component: a retrospective case study, immunohistochemical analysis and literature review. Singap Med J. 2012;53(3):e49\u201351.","journal-title":"Singap Med J"},{"issue":"4","key":"2252_CR28","doi-asserted-by":"publisher","first-page":"188928","DOI":"10.1016\/j.bbcan.2023.188928","volume":"1878","author":"L Zhang","year":"2023","unstructured":"Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities. Biochim Biophys Acta Rev Cancer. 2023;1878(4):188928.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"9","key":"2252_CR29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.diii.2021.04.004","volume":"102","author":"E Zampella","year":"2021","unstructured":"Zampella E, Klain M, Pace L, Cuocolo A. PET\/CT in the management of differentiated thyroid cancer. Diagn Interv Imaging. 2021;102(9):515\u201323.","journal-title":"Diagn Interv Imaging"},{"issue":"1","key":"2252_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13139-024-00885-y","volume":"59","author":"SW Oh","year":"2025","unstructured":"Oh SW, Park S, Chong A, Kim K, Bang JI, Seo Y, et al. Nuclear Medicine Imaging in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-I. Nucl Med Mol Imaging. 2025;59(1):1\u20137.","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"2252_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017;168(4):613\u201328.","journal-title":"Cell"},{"issue":"10","key":"2252_CR32","first-page":"1727","volume":"39","author":"T Higashi","year":"1998","unstructured":"Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39(10):1727\u201335.","journal-title":"J Nucl Med"},{"issue":"4","key":"2252_CR33","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/BF00311254","volume":"25","author":"K Sugino","year":"1995","unstructured":"Sugino K, Kure Y, Iwasaki H, Ozaki O, Mimura T, Matsumoto A, et al. Metastases to the regional lymph nodes, lymph node recurrence, and distant metastases in nonadvanced papillary thyroid carcinoma. Surg Today. 1995;25(4):324\u20138.","journal-title":"Surg Today"},{"key":"2252_CR34","doi-asserted-by":"crossref","unstructured":"Aashiq M, Silverman DA, Na\u2019ara S, Takahashi H, Amit M. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies. Cancers (Basel) 2019; 11 (9).","DOI":"10.3390\/cancers11091382"},{"key":"2252_CR35","doi-asserted-by":"crossref","unstructured":"Enke JS, Bundschuh RA, Wienand G, Reitsam NG, Kircher M, Pfob CH et al. Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma. J Nuclear Med 2023:jnumed.123.265639.","DOI":"10.2967\/jnumed.123.265639"},{"issue":"2","key":"2252_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s13139-015-0324-6","volume":"49","author":"JW Lee","year":"2015","unstructured":"Lee JW, Min HS, Lee SM, Kwon HW, Chung JK. Relations Between Pathological Markers and Radioiodine Scan and (18)F-FDG PET\/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases. Nucl Med Mol Imaging. 2015;49(2):127\u201334.","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"2252_CR37","first-page":"76","volume":"54","author":"M Middendorp","year":"2010","unstructured":"Middendorp M, Selkinski I, Happel C, Kranert WT, Grunwald F. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imaging. 2010;54(1):76\u201383.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"7","key":"2252_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1517\/17530059.2.7.829","volume":"2","author":"K Kurdziel","year":"2008","unstructured":"Kurdziel K, Ravizzini G, Croft B, Tatum J, Choyke P, Kobayashi H. The evolving role of nuclear molecular imaging in cancer. Expert Opin Med Diagn. 2008;2(7):829\u201342.","journal-title":"Expert Opin Med Diagn"},{"issue":"10","key":"2252_CR39","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1210\/jc.2006-0825","volume":"91","author":"M Rodrigues","year":"2006","unstructured":"Rodrigues M, Li S, Gabriel M, Heute D, Greifeneder M, Virgolini I. 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J Clin Endocrinol Metab. 2006;91(10):3997\u20134000.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2252_CR40","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1186\/s12885-025-15036-5","volume":"25","author":"G Wang","year":"2025","unstructured":"Wang G, Feng F, Huang S, Li C. Clinical outcomes by bone metastasis uptake pattern in differentiated thyroid cancer. BMC Cancer. 2025;25(1):1617.","journal-title":"BMC Cancer"},{"key":"2252_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/jcm13133963","volume":"13","author":"D Diwanji","year":"2024","unstructured":"Diwanji D, Carrodeguas E, Seo Y, Kang H, Soe MH, Chiang JM, et al. Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers. J Clin Med. 2024;13:13.","journal-title":"J Clin Med"},{"issue":"7","key":"2252_CR42","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00259-022-05697-w","volume":"49","author":"A Jannin","year":"2022","unstructured":"Jannin A, Lamartina L, Moutarde C, Djennaoui M, Lion G, Chevalier B, et al. Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival. Eur J Nucl Med Mol Imaging. 2022;49(7):2401\u201313.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2252_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13139-013-0239-z","volume":"48","author":"DH Kim","year":"2014","unstructured":"Kim DH, Jung JH, Son SH, Kim CY, Hong CM, Jeong SY, et al. Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer. Nucl Med Mol Imaging. 2014;48(1):55\u201362.","journal-title":"Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02252-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02252-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02252-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:02:50Z","timestamp":1792522970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02252-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2252"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02252-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9194234\/v1","asserted-by":"object"}]},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Joon Ho Choi, Jae Kyung Myung, Ji Eun Moon, Joon-Seog Kong, Byung Hyun Byun, Byung Il Kim, Ilhan Lim declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board at the Korea Cancer Center Hospital (IRB No. KIRAMS 2019\u2009\u2212\u200902\u2212008). All procedures of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board of our institute approved this retrospective study, and the requirement to obtain informed consent was waived.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}